PRODUCT INFORMATION

VcMMAE

Item No. 35646



CAS Registry No.: 646502-53-6
Formal Name: N-[[[4-[[N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N^5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide
Synonyms: MC-VC-PAB-MMAE, Vedotin
MF: $C_{68}H_{105}N_{11}O_{15}$
FW: 1,316.6
Purity: ≥98%
UV/Vis.: λ_{max}: 251 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

VcMMAE is supplied as a solid. A stock solution may be made by dissolving the VcMMAE in the solvent of choice, which should be purged with an inert gas. VcMMAE is soluble in ethanol and DSMO.

Description

VcMMAE is a drug-linker molecule that has been used in the synthesis of antibody-drug conjugates (ADCs).[1,2] It contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody, a protease-cleavable peptide linker, and the antimitotic and anticancer agent monomethyl auristatin E (MMAE; Item No. 16267).

References

1. Chuprakov, S., Ogunkoya, A.O., Barfield, R.M., *et al.* Tandem-cleavage linkers improve the *in vivo* stability and tolerability of antibody-drug conjugates. *Bioconjug. Chem.* **32(4),** 746-754 (2021).
2. Dimou, M., Papageorgiou, S.G.S., N., Katodritou, E., *et al.* Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. *Hematol. Oncol.* **39(3),** 336-348 (2021).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM